Catalent

With global development and manufacturing sites, Catalent combines its formulation and bioavailability enhancement experience, along with delivery technologies to support the launch of more than 100 new products every year.

Catalent’s site in Anagni, Italy offers extensive capabilities in aseptic liquid and powder filling, as well as comprehensive packaging solutions to support product launches for oral solids, sterile, and biologics products.

The application of a phase-appropriate quality-by-design (QbD) framework increases the understanding of the interplay between the process parameters of spray drying and product quality that, when applied during scale-up, increases the chances of a successful outcome of the commercial manufacturing process. Live: Tuesday, November 19, 2019 at 10am EST | 9am CST | 3pm GMT | 4pm CET On demand available after airing until Nov. 19, 2020 Register free

Join this webcast to learn how to avoid common pitfalls in the tech transfer and scale-up process using an integrated approach. Live: Thursday, Oct. 24, 2019 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after airing until Oct. 24, 2020 Register free

Join experts for a discussion on how contracting with a single service provider can offer significant benefits to the customer. Live: Tuesday, Sept. 24, 2019 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after airing until Sept. 24, 2020 Register free

This webcast will describe one solution: Working with a clinical supply partner to handle the packaging and potential complex distribution logistics for expanded access programs and commercial supply. Live: Thursday, Sept. 19, 2019 10am EDT | 9am CDT | 3pm BST | 4pm CEST On demand available after airing until Sept. 19, 2020 Register free

With global development and manufacturing sites, Catalent combines its formulation and bioavailability enhancement experience, along with delivery technologies to support the launch of more than 100 new products every year.

Catalent offers its partners a wide range of innovative oral dose technologies that can benefit drug developers, and help to improve convenience and patient compliance, while reducing pill burden, which is especially important for vulnerable patient populations.

Catalent Pharma Solutions offers its partners end-to-end solutions, from early drug product development, formulation and drug delivery technologies, to manufacturing and global clinical supply services.

To match the growing demand for biopharmaceutical development and manufacturing, Catalent Biologics has invested extensively in its network to create a comprehensive end-to-end offering for its customers.

Catalent partners with innovators to accelerate programmes through the early phases of development, overcome a molecule’s solubility and bioavailability challenges, and increase its likelihood of success in the clinic.

The acquisition and integration of Cook Pharmica LLC’s business and facility into Catalent’s global biologics network facilities allow its clients to benefit from end-to-end solutions in biologic drug development.

Catalent partners with innovators to accelerate programmes through the early phases of development, overcome a molecule’s solubility and bioavailability challenges, and increase its likelihood of success in the clinic.

Catalent has the broadest range of technologies and solutions to overcome developmental and bioavailability challenges, and to enhance product performance.

With the acquisition of Pharmatek Laboratories, Catalent now offers spray drying as part of its bioavailability toolkit, complementing its comprehensive suite of development and formulation solutions.

Catalent combines its formulation expertise, manufacturing excellence and particle size reduction technologies to provide a broad range of solutions in the development of inhalation and nasal drug products.

As more drug companies adopt comparative effectiveness studies, drug supply professionals are challenged with sourcing and managing comparator drugs. This ebook examines research from the Tufts Center for the Study of Drug Development, and reviews the pros and cons of the transactional and strategic comparator sourcing models to aid in the development of effective sourcing approaches. Special considerations, and commonly encountered issues in biologics sourcing are discussed. In addition, areas to consider in equivalence testing for comparability are reviewed.